18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer
Status:
Recruiting
Trial end date:
2023-09-12
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies how well fluorine F 18 d-FMAU (18F-FMAU) positron emission
tomography (PET)/computed tomography (CT) works in diagnosing and characterizing prostate
cancer. A PET/CT scan is an imaging test that uses a small amount of radioactive tracer that
is given through the vein to take detailed pictures of areas inside the body where the tracer
is taken up. Radiotracers such as 18F-FMAU may help to find the cancer and see how far the
disease has spread.
Phase:
Phase 1
Details
Lead Sponsor:
University of Southern California
Collaborators:
National Cancer Institute (NCI) National Institute for Biomedical Imaging and Bioengineering (NIBIB)